Biogen, Sage prep 2022 filing for depression drug zuranoloneThe renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to Share XBiogen, Sage prep 2022 filing for depression drug zuranolonehttps://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/
Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
